BioSpace News Archive

Deals

AbbVie Continues Buying Spree with $8.7B Cerevel Acquisition to Bolster Neuro

The deal, announced late Wednesday, will provide AbbVie with access to Cerevel Therapeutics’ pipeline of clinical-stage and preclinical candidates for psychiatric and neurological diseases.

December 7, 2023
·
2 min read
·
Tristan Manalac
Policy

Biden Admin Targets Pharma Patents to Lower Drug Prices under Controversial Authority

Following a nine-month review, the Biden administration will issue a framework for the National Institutes of Health to implement so-called “march-in rights” under the Bayh-Dole Act of 1980.

December 7, 2023
·
3 min read
·
Tristan Manalac
Business

How Kyowa Kirin is Giving Employees a Voice in the Company’s Future

Five years ago, Kyowa Kirin set out to expand its North America operations, adding new employees and capabilities at a rapid pace. The Human Resources team ensures employee input is central to managing that growth and nurturing a culture to support it

December 7, 2023
·
4 min read
·
Britt Byers, Senior Vice President of Human Resources, Kyowa Kirin North America
Sanofi Touts 12 Potential Blockbusters in Bid to Regain Investor Confidence

In an R&D event on Thursday, the French pharma is trying to win over its investors by highlighting a dozen potential blockbusters and charting strong growth for the company through 2030.

December 7, 2023
·
2 min read
·
Tristan Manalac
Employer Resources

Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA

In this episode, hear from senior leaders at Microsoft and IQVIA to get their take on how generative AI is impacting productivity, employee engagement and how to mitigate risks.

December 7, 2023
·
1 min read
·
BioSpace Insights
Drug Development

High Response Rate for Regeneron’s Myeloma Bispecific Marred by AEs

While almost half of multiple myeloma patients on linvoseltamab achieved a complete response or better, all experienced adverse events and 14 patients died due to treatment-emergent AEs.

December 7, 2023
·
2 min read
·
Kate Goodwin
Drug Development

Merck’s Keytruda, Anti-TIGIT Combo Fails Phase II NSCLC Trial

A combination of Merck’s experimental anti-TIGIT antibody vibostolimab and anti-PD-1 drug Keytruda failed to hit its endpoints in a mid-stage non-small cell lung cancer study.

December 7, 2023
·
2 min read
·
Tyler Patchen
Genetown

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

Ipsen, a global specialty-driven biopharmaceutical company, holds its Capital Markets Day in London, U.K.

December 7, 2023
·
7 min read
Business

Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage

Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer.

December 7, 2023
·
4 min read
Policy

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Ipsen and GENFIT announced that the U.S. Food and Drug Administration has accepted the New Drug Application for investigational elafibranor.

December 7, 2023
·
14 min read